Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
TScan Therapeutics, Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05473910CT.gov A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adult Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tsc-101 (this asset) | TScan Therapeutics, Inc. | P1 | CC · 43 |
| Mercaptopurine Anhydrous | Shanxi Bethune Hospital | P4 | A |
| Dexasone | Shanxi Bethune Hospital | P4 | BBB |
| Cytarabine | PETHEMA Foundation | P4 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Zhengzhou University | P4 | BBB |
| Asparaginase | Institute of Hematology & Blood Diseases Hospital, China | P4 | BBB |
| Vindesine | Shanxi Bethune Hospital | P4 | BBB |
| Adriamycin | University of Washington | P4 | BBB |
| Methotrexate | PETHEMA Foundation | P4 | BBB |
+42 more in the Adult Acute Lymphoblastic Leukemia cohort
Other indications for Tsc-101
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P1 | C · 39 |
| Myelodysplastic Syndrome | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tsc-101 in Adult Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tsc-101-adult-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →